Telomir Pharmaceuticals, Inc. Increase (Decrease) in Accounts Payable and Accrued Liabilities
Telomir Pharmaceuticals, Inc. (TELO) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$341.24 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-13
- Telomir Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was -$84.09K.
- Telomir Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$257.15K.
- Telomir Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $207.39K, a 155.87% increase year-over-year.
- Telomir Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $74.42K, a 33.95% decline year-over-year.
- Telomir Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was -$50.77K, a 127.65% decline from fiscal 2024.
- Telomir Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was $183.63K, a 60.30% increase from fiscal 2023.
- Telomir Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $114.56K, a 70.28% decline from fiscal 2022.
- Telomir Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $385.49K.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$84.09K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$341.24K 10-Q · filed 2026-08-13 | -$133.85K derived: sum of 3 quarters · filed 2026-08-13 | -$59.43K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$257.15K 10-Q · filed 2026-05-14 | -$49.76K derived: sum of 2 quarters · filed 2026-05-14 | $24.66K derived: sum of 3 quarters · filed 2026-05-14 | -$279.25K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $207.39K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $281.81K derived: sum of 2 quarters · filed 2026-03-17 | -$22.09K derived: sum of 3 quarters · filed 2026-08-13 | -$50.77K 10-K · filed 2026-03-17 |
| 2025-09-30 | $74.42K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$229.49K derived: sum of 2 quarters · filed 2026-08-13 | -$258.16K 10-Q · filed 2025-11-10 | -$177.11K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$303.90K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$332.58K 10-Q · filed 2026-08-13 | -$251.53K derived: sum of 3 quarters · filed 2026-08-13 | -$138.86K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$28.68K 10-Q · filed 2026-05-14 | $52.38K derived: sum of 2 quarters · filed 2026-05-14 | $165.04K derived: sum of 3 quarters · filed 2026-05-14 | $80.21K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $81.06K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $193.72K derived: sum of 2 quarters · filed 2026-03-17 | $108.89K derived: sum of 3 quarters · filed 2026-03-17 | $183.63K 10-K · filed 2026-03-17 |
| 2024-09-30 | $112.67K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $27.83K derived: sum of 2 quarters · filed 2025-11-10 | $102.57K 10-Q · filed 2025-11-10 | $125.32K derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$84.83K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$10.09K 10-Q · filed 2025-08-14 | $12.66K derived: sum of 3 quarters · filed 2025-08-14 | -$1.04M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $74.74K 10-Q · filed 2025-05-14 | $97.49K derived: sum of 2 quarters · filed 2025-05-14 | -$950.65K derived: sum of 3 quarters · filed 2025-05-14 | $442.10K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $22.75K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-04 | -$1.03M derived: sum of 2 quarters · filed 2025-02-04 | $367.36K derived: sum of 3 quarters · filed 2025-02-04 | $114.56K 10-K · filed 2025-02-04 |
| 2023-09-30 | -$1.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $344.61K derived: sum of 2 quarters · filed 2024-11-12 | $91.81K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $1.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $1.14M 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | -$252.80K 10-Q · filed 2024-05-13 | |||
| 2022-12-31 | $385.49K 10-K · filed 2024-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |